Das Zentrum
Multiple Sklerose Zentrum Dresden
Patienteninformation
Kontaktinformation
Behandlungsteam
Studienteam
Neuropsychologie
Mobilitätszentrum
Das Mobilitätszentrum
Ganganalyse
Sprunganalyse
DIERS
EMIQ
Forschungsprojekte
Neuroimmunologisches Labor
Das NIL
Neurofilament-Leichtketten Analyse
Autonomes & Neuroendokrinologisches Funktionslabor
Das ANF
Untersuchungsmethoden
MS Living Lab
Management & Science
Team Management & Science
Projekte
eHealth & Analytics
MSDS 3D
MSDS Klinik & Praxis
MS-HRS
MTRS
MS Management
Aktuelles
Neuigkeiten
Publikationen
Veranstaltungen
Adventssymposium
Multiple Sklerose 360°
Welt-MS-Tag 2021
Doktorarbeiten
Jobs
Kontakt
Podcasts & Newsletter
Newsletter
Patienten-Podcast
Ärzte-Podcast
Studien
Interventionelle Studien
B-SHUTTLE
Nicht-interventionelle Studien
MS PATHS
Konectom
Sprachanalyse
Deutsch
Deutsch
English (UK)
Using machine learning algorithms to detect fear of falling in people with multiple sclerosis in standardized gait analysis
Mobility
Jahr
Publikationsjahr
2024
Autoren
Autorenliste der Publikation
Schumann P, Trentzsch K, Stölzer-Hutsch H, Jochim T, Scholz M, Malberg H, Ziemssen T.
Verlag
Publisher-Information
Mult Scler Relat Disord. 2024 Jun 10;88:105721.
Link
Zur Publikation (externer Server)
https://doi.org/10.1016/j.msard.2024.105721
Tags
Forschungsthemen
Multiple Sklerose
Mobilität
Management & Science
MSZ
MASC
2024
MOBI
Comparative efficacy of diroximel fumarate, ozanimod and interferon beta-1a for relapsing multiple sclerosis using matching-adjusted indirect comparisons
MS Treatments
Jahr
2024
Evaluation of therapy satisfaction with cladribine tablets in patients with RMS: Final results of the non-interventional study CLEVER
MS Treatments
Jahr
2024
Change from platform to high efficacy disease-modifying treatment for multiple sclerosis despite NEDA
MS Treatments
Jahr
2024
Rule-Based DSL for Continuous Features and ML Models Selection in Multiple Sclerosis Research
MASC
Jahr
2024
Real-world evidence from Germany and the United States: Treatment initiation on low-efficacy versus high-efficacy therapies in patients with multiple sclerosis
MS Treatments
Jahr
2024
